Forkhead box protein O1 (FOXO1) (FOXO1)

Forkhead box protein O1 (FOXO1) is a pivotal transcription factor that integrates environmental and nutritional signals to regulate metabolic homeostasis, cell survival, and growth (UniProt P12748). As a primary downstream effector of the insulin and PI3K/AKT signaling pathways, FOXO1 acts as a metabolic switch: in the absence of insulin, it resides in the nucleus to promote the expression of genes involved in gluconeogenesis and glycogenolysis, such as G6PC and PEPCK (Wikipedia, 2024). Conversely, insulin-mediated phosphorylation by AKT leads to its nuclear exclusion and subsequent degradation, thereby suppressing hepatic glucose output (PubChem, 2024). In pathology, FOXO1 dysregulation is central to the development of Type 2 diabetes and various malignancies. Chronic overactivation in the liver contributes to hyperglycemia, while its role as a tumor suppressor is often compromised in cancers through inhibitory phosphorylation or genetic translocations, such as the PAX3-FOXO1 fusion found in alveolar rhabdomyosarcoma (PMC86620). Pharmacological strategies focus on small-molecule inhibitors like AS1842856 to treat metabolic diseases by reducing excessive glucose production, though achieving tissue-specific modulation remains a significant therapeutic challenge due to its pleiotropic roles in the pancreas, adipose tissue, and immune system (Frontiers in Endocrinology, 2023).

Other names

Forkhead in rhabdomyosarcomaFKHRFOXO1AForkhead box protein O1AFKH1

Direct binding to the active (unphosphorylated) transcription factor to inhibit DNA binding and transcriptional activity, or indirect modulation of nuclear-cytoplasmic translocation via AKT-mediated phosphorylation and deacetylation.